No Data
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12
Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Cathie Wood's ARK Investment Buys 383K Shares of Recursion Pharmaceuticals Today
Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
No Data
No Data
Space Dust : all ai needs for drug discovery is to find old literature before pharma took over the AMA. pharma is just synthesizing old natural cures and putting a patent on them..
ELEVENjonny :
骨神 : Today down due to nivadia